Future Medicine Co., Ltd.
Future Medicine develops FM101, FM301, FM2L and FM801 for MASH, glaucoma, cancer and obesity via its FOCUS platform.
As of 2026-10-10, Future Medicine Co., Ltd. has 36 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2015 and listed on KONEX in 2022, Future Medicine is a synthetic drug developer. Using its nucleoside-derivative FOCUS platform, it develops FM101 for MASH, glaucoma, diabetic nephropathy and PBC, plus FM301, FM2L and FM801. FM101 completed European Phase 1 for MASH and entered Phase 2a, gained Australian IND approval for glaucoma, and received US FDA rare disease status for PBC.
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2023 (Phase 2a 1)
- Phase 2aFM1012023-02-01
10 trial sites
Global clinical trials
ClinicalTrials.gov · sponsor-matched- FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
Phase 2 · Unknown · 2021-06 · NCT04710524
Phase 1/2 · Unknown · 2020-10 · NCT04585100
Phase 1 · Completed · 2019-01 · NCT03879928
R&D and key agreements
Source: DART corporate disclosureFM101 · 대사이상지방간염(MASH) · 유럽 임상1상 종료, 유럽/한국 다국가 임상2a상 진행 중 · Anti-inflammatory/anti-fibrotic candidate
FM101 · 녹내장(Glaucoma) · 유럽 임상1상 종료, 호주 임상2a상 IND 승인 · Anti-inflammatory/anti-fibrotic candidate
FM101 · 당뇨병성 신증 · 유럽 임상1상 종료 · Anti-inflammatory/anti-fibrotic candidate
FM101 · 원발성 담즙성 담관염(PBC) · 유럽 임상1상 종료 · Designated as a rare disease treatment by the US FDA
FM301 · 폐암, 대장암 등 · 비임상 진행 중 · Multi-target anticancer agent
FM2L · COVID-19 · 비임상 진행 중 · Antiviral agent
FM801 · 비만 · 비임상 진행 중 · Obesity treatment candidate
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- 4'-Thionucleosides as adenosine A3 receptor ligands: a medicinal chemistry perspective.
Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026-04 · Kim HR, Jeong LS
- Structure-activity relationship analysis of 5'-substituted C2-hexynyl-4'-thioadenosine analogs as dual A2A/A3 adenosine receptor agonists with tunable selectivity and anti-inflammatory activity.
European journal of medicinal chemistry · 2026-01 · Kim SW, Bok J, Choi H 외 4
- Comparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain.
Archives of pharmacal research · 2025-12 · Kim H, Kim SW, Choi C 외 8
- Design, Synthesis, and Biological Evaluation of C2-(N-Substituted Amino) Truncated 4'-Thioadenosine Derivatives as A2AAR and A3AR Dual Ligands.
ACS medicinal chemistry letters · 2025-12 · Joung M, Choi H, Kim M 외 7
- Discovery of a Novel Template, N3‑1'-Homologated 4'-Truncated Thiosugar-Substituted Xanthine as an A3AR Antagonist via Conversion of an A1AR Antagonist.
ACS medicinal chemistry letters · 2025-12 · Joung M, Kim M, Choi H 외 7
- Design, Synthesis, and Biological Evaluation of 5',7-Disubstituted 7-Deaza-adenosine Analogues as Irreversible Pan-FGFR Inhibitors.
Pharmaceuticals (Basel, Switzerland) · 2025-11 · Park JH, Tran PT, Ko HL 외 13
- Design, Synthesis, and Antiviral Activity of 8‑Aza Fluoroneplanocin Derivatives Targeting SAH Hydrolase and Viral RdRp.
ACS medicinal chemistry letters · 2025-11 · Song J, Choi H, Kim M 외 8
- Design and development of 5'-modified 7-substituted 4'-thionucleosides as potent Haspin inhibitors: Synthesis and biological evaluation.
Bioorganic chemistry · 2025-11 · Yum YA, Jang SC, Kim SW 외 8
- Regio- and Stereoselective Ribose Modification in Truncated 2,8-Disubstituted Adenosine Scaffold to Develop Highly Potent A2A Adenosine Receptor Antagonists.
Journal of medicinal chemistry · 2025-08 · Kim G, Kim SW, Choi H 외 6
- Targeting HASPIN in gemcitabine-resistant pancreatic cancer cells by lead optimization of thioadenosine analogue.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025-07 · Shin YZ, Yum YA, Bae ES 외 9
Show 26 more publications
- Identification of 4'-Thiouridine as an Orally Available Antiviral Agent Targeting Both RdRp and NiRAN Functions of SARS-CoV-2 Nsp12.
Journal of medicinal chemistry · 2025-06 · Kim M, Lee MK, Jo I 외 11
- Steric influence of 4'-position substituents and C2-Hexynyl group on A3AR antagonism in truncated 4'-Thioadenosine derivatives.
Bioorganic chemistry · 2025-06 · Kim M, Kim J, Tripathi SK 외 7
- Design, synthesis, and biological evaluation of 5'-deoxy (N)-methanocarbanucleoside derivatives as A3 adenosine receptor ligands.
Bioorganic & medicinal chemistry letters · 2025-05 · Kim M, Naik SD, Kim SW 외 4
- Structure-Activity Relationship Analysis of 2-Aryl-8-alkynyl Adenine and Nucleoside Scaffolds as A3 Adenosine Receptor Ligands.
ACS medicinal chemistry letters · 2025-05 · Kim G, Lee G, Jarhad DB 외 5
- A3AR antagonism mitigates metabolic dysfunction-associated steatotic liver disease by exploiting monocyte-derived Kupffer cell necroptosis and inflammation resolution.
Metabolism: clinical and experimental · 2025-03 · Park JS, Ma YQ, Wang F 외 11
- Synthesis and Biological Evaluation of 5'-Deoxy-adenosine Derivatives as A3 Adenosine Receptor Ligands.
ACS medicinal chemistry letters · 2025-01 · Kim M, Naik SD, Choi H 외 7
- Design, synthesis and biological evaluation of truncated 1'-homologated 4'-selenonucleosides as PPARγ/δ dual modulators.
Bioorganic chemistry · 2025-01 · Choi H, An S, Hyun YE 외 2
- Synthesis and biological evaluation of sugar-modified truncated carbanucleosides as A2A and A3 adenosine receptor ligands to explore conformational effect to the receptors.
Bioorganic & medicinal chemistry · 2024-12 · Kim M, Hyun YE, Kang SY 외 4
- Stereochemical influence of 4'-methyl substitutions on truncated 4'-thioadenosine derivatives: Impact on A3 adenosine receptor binding and antagonism.
Bioorganic chemistry · 2024-12 · Kim M, Naik SD, Jarhad DB 외 5
- Structure-Activity Relationship of Truncated 4'-Selenonucleosides: A3 Adenosine Receptor Activity and Binding Selectivity.
ACS medicinal chemistry letters · 2024-09 · Kim M, Choi H, Nayak A 외 5
- Structural Modification and Biological Evaluation of 2,8-Disubstituted Adenine and Its Nucleosides as A2A Adenosine Receptor Antagonists: Exploring the Roles of Ribose at Adenosine Receptors.
Journal of medicinal chemistry · 2024-06 · Kim G, Jarhad DB, Lee G 외 19
- Structure-Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A2A/A3 Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity.
Journal of medicinal chemistry · 2023-09 · Kim G, Hou X, Byun WS 외 17
- In Silico Discovery of 5'-Modified 7-Deoxy-7-ethynyl-4'-thioadenosine as a HASPIN Inhibitor and Its Synergistic Anticancer Effect with the PLK1 Inhibitor.
ACS central science · 2023-06 · Kwon EJ, Mashelkar KK, Seo J 외 11
- Structure-Activity Relationships of Truncated 1'-Homologated Carbaadenosine Derivatives as New PPARγ/δ Ligands: A Study on Sugar Puckering Affecting Binding to PPARs.
Journal of medicinal chemistry · 2023-04 · Hyun YE, An S, Kim M 외 12
- A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway.
Acta pharmaceutica Sinica. B · 2023-03 · Yoon SB, Hong H, Lim HJ 외 11
- Anticancer activity of IRAK-4 inhibitors against canine lymphoid malignancies.
Veterinary and comparative oncology · 2022-09 · Park JH, Lee JH, An JH 외 5
- Discovery of a Novel Template, 7-Substituted 7-Deaza-4'-Thioadenosine Derivatives as Multi-Kinase Inhibitors.
Pharmaceuticals (Basel, Switzerland) · 2021-12 · Mashelkar KK, Byun WS, Ko H 외 12
- Analytical method development and percutaneous absorption of propylidene phthalide, a cosmetic ingredient.
Journal of toxicology and environmental health. Part A · 2021-10 · Kim JY, Im JE, Lee JD 외 1
- Dual Actions of A2A and A3 Adenosine Receptor Ligand Prevents Obstruction-Induced Kidney Fibrosis in Mice.
International journal of molecular sciences · 2021-05 · Pak ES, Jeong LS, Hou X 외 3
- Discovery and Structure-Activity Relationships of Novel Template, Truncated 1'-Homologated Adenosine Derivatives as Pure Dual PPARγ/δ Modulators.
Journal of medicinal chemistry · 2020-12 · An S, Kim G, Kim HJ 외 18
- 6'-β-Fluoro-Homoaristeromycin and 6'-Fluoro-Homoneplanocin A Are Potent Inhibitors of Chikungunya Virus Replication through Their Direct Effect on Viral Nonstructural Protein 1.
Antimicrobial agents and chemotherapy · 2020-03 · Kovacikova K, Morren BM, Tas A 외 10
- Correlation study between A3 adenosine receptor binding affinity and anti-renal interstitial fibrosis activity of truncated adenosine derivatives.
Archives of pharmacal research · 2019-09 · Yu J, Kim G, Jarhad DB 외 5
- Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues.
Journal of medicinal chemistry · 2019-07 · Yoon JS, Kim G, Jarhad DB 외 15
- Small-molecule inhibitor of HlyU attenuates virulence of Vibrio species.
Scientific reports · 2019-03 · Lee ZW, Kim BS, Jang KK 외 12
- Orally active, species-independent novel A3 adenosine receptor antagonist protects against kidney injury in db/db mice.
Experimental & molecular medicine · 2018-04 · Dorotea D, Cho A, Lee G 외 6
- Determination and validation of LJ-2698, a potent human A3 adenosine receptor antagonist, in rat plasma by liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic study.
Archives of pharmacal research · 2017-08 · Lee JY, Park JH, Kim KT 외 9
Patents
KIPRIS · applicant-matchedWithdrawn · 2026-03 · Application 1020260042117
US · Published · 2024-07 · Application 18784715
Withdrawn · 2024-06 · Application 1020240075326
Withdrawn · 2024-02 · Application 1020240021345
CN · Published · 2023-07 · Application 202380055851.3
US · Published · 2023-07 · Application 18997516
EP · Published · 2023-07 · Application 23843428.6
Withdrawn · 2023-06 · Application 1020230080806
Abandoned · 2023-03 · Application 1020230039943
PCT · Published · 2023-03 · Application PCT/KR2023/003958
Show 64 more patents
Withdrawn · 2022-08 · Application 1020220096040
Registered · 2022-07 · Application 1020220091348
US · Registered · 2022-07 · Application 17866990
Withdrawn · 2022-07 · Application 1020220087503
CN · Published · 2022-05 · Application 202280041325.7
US · Published · 2022-05 · Application 18568288
EP · Published · 2022-05 · Application 22820464.0
PCT · Published · 2022-05 · Application PCT/KR2022/007747
US · Published · 2022-03 · Application 18283478
EP · Published · 2022-03 · Application 22776127.7
PCT · Published · 2022-03 · Application PCT/KR2022/004147
Registered · 2022-03 · Application 1020220036750
US · Published · 2022-02 · Application 18277982
EP · Published · 2022-02 · Application 22759972.7
PCT · Published · 2022-02 · Application PCT/KR2022/002329
US · Published · 2022-01 · Application 17585493
US · Published · 2022-01 · Application 17585497
US · Published · 2022-01 · Application 18578736
PCT · Published · 2022-01 · Application PCT/KR2022/001293
CN · Published · 2021-11 · Application 202180079391.9
US · Published · 2021-11 · Application 18038444
EP · Published · 2021-11 · Application 21898573.7
EP · Published · 2021-11 · Application 21210303.0
PCT · Published · 2021-11 · Application PCT/KR2021/017325
Expired · 2021-11 · Application 1020210162291
US · Registered · 2021-08 · Application 17458231
Rejected · 2021-06 · Application 1020210082247
Registered · 2021-06 · Application 1020210073914
Expired · 2021-02 · Application 1020210026365
Expired · 2020-03 · Application 1020200037371
Expired · 2019-10 · Application 1020190121342
PCT · Published · 2019-06 · Application PCT/NL2019/050328
CN · Published · 2018-11 · Application 202210596951.4
CN · Published · 2018-11 · Application 201880077439.0
US · Published · 2018-11 · Application 16767489
EP · Registered · 2018-11 · Application 18883014.5
PCT · Published · 2018-11 · Application PCT/KR2018/014943
CN · Published · 2018-07 · Application 202410170774.2
CN · Published · 2018-07 · Application 201880045444.3
US · Registered · 2018-07 · Application 16618396
EP · Registered · 2018-07 · Application 23178716.9
EP · Registered · 2018-07 · Application 18827831.1
PCT · Published · 2018-07 · Application PCT/KR2018/007717
JP · Registered · 2018-07 · Application 32500619
US · Registered · 2018-03 · Application 16492938
EP · Registered · 2018-03 · Application 18771758.2
PCT · Published · 2018-03 · Application PCT/KR2018/003274
JP · Registered · 2018-03 · Application 31547971
PCT · Published · 2018-01 · Application PCT/KR2018/000644
Registered · 2017-11 · Application 1020170161545
Rejected · 2017-11 · Application 1020170152698
TW · Registered · 2017-10 · Application 106137294
US · Registered · 2017-10 · Application 16345724
EP · Registered · 2017-10 · Application 17864072.8
PCT · Published · 2017-10 · Application PCT/KR2017/011744
JP · Registered · 2017-10 · Application 31520614
Registered · 2017-07 · Application 1020170086703
Rejected · 2017-06 · Application 1020170071369
Abandoned · 2017-05 · Application 1020170063574
Rejected · 2017-03 · Application 1020170040433
Registered · 2017-03 · Application 1020170035224
Rejected · 2017-01 · Application 1020170005061
Registered · 2016-10 · Application 1020160142723
PCT · Published · 2016-09 · Application PCT/KR2016/010746
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive3
- OpenAIOAI-SearchBot14
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Future Medicine Co., Ltd. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition